Wordt geladen...

Dysregulation of mTOR activity through LKB1 inactivation

Mammalian target of rapamycin (mTOR) is aberrantly activated in many cancer types, and two rapamycin derivatives are currently approved by the Food and Drug Administration (FDA) of the United States for treating renal cell carcinoma. Mechanistically, mTOR is hyperactivated in human cancers either du...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Zhou, Wei, Marcus, Adam I., Vertino, Paula M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Sun Yat-sen University Cancer Center 2013
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3845579/
https://ncbi.nlm.nih.gov/pubmed/23668926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.013.10086
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!